Graff Jeremy R. 4

What Happened

• Jeremy R. Graff, a director of IN8BIO, was granted a derivative award for 22,000 shares on May 9, 2026. The reported acquisition price is $0.00, so the Form 4 lists no immediate cash value. This was an award/grant (not a sale or open‑market purchase).

Key Details

• Transaction date: 2026-05-09; Form 4 filed: 2026-05-12.
• Reported securities: 22,000 shares (derivative award) at $0.00 per share; total reported cash value = $0.
• Vesting: One-twelfth (1/12) of the shares vest in equal monthly installments beginning June 9, 2026; the award will be fully vested by the company’s next annual meeting of stockholders, provided Graff continues service (see footnote F1).
• Filing timeliness: Form shows the filing date; the report does not state a tardiness designation.
• Shares owned after the transaction: Not specified in the reported items on this Form 4.

Context

• The $0.00 price and the explicit monthly vesting schedule indicate this is a time‑vesting equity award (derivative grant), not an immediate exercise or sale. Such grants are common as compensation for directors and typically vest over time contingent on continued service. This filing documents the grant; it does not in itself indicate buying or selling sentiment.